Cytomedix says proposed National Coverage Determination memo by CMS includes proposal through CED for all three major wound categories; conference call May 10 (CMXI)
Cytomedix, Inc. (CMXI.OB) is a biotechnology company developing advanced tissue regeneration technologies. Its primary focus is on commercializing autologous cell based therapies that facilitate the body’s natural healing processes for enhanced healing and tissue repair. Its commercial portfolio is based on autologous platelet rich plasma (“PRP”) platform technology, and includes the Angel® Whole Blood Separation System (“Angel®”) and the AutoloGelTM System (“AutoloGel”).
In the CED process, CMS provides payment for items and services while generating additional clinical data to demonstrate their impact on health outcomes. Cytomedix says that the proposed decision by CMS bodes well for its ongoing discussions with a top 20 global pharmaceutical company for an exclusive U.S. supply and distribution agreement for AutoloGel in wound care.
A Company conference call was held 10-May at 9:00 ET to discuss the proposed NCD and the CED initiatives. A replay of the conference call will be available beginning two hours after its completion through May 17, 2012 by dialing 888-286-8010 (domestic) or 617-801-6888 international) and entering passcode 61561051. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.cytomedix.com.